First-of-its-kind treatment shows ‘dramatic’ effect on children with eczema: ScienceAlert

Eczema (or atopic dermatitis) affects millions of people, especially children under the age of six.

A chronic inflammatory skin disorder causes the skin to become red, dry, ooze, and itch, making life very uncomfortable.

There is currently no cure for this condition, only ways to manage it – but the current medication is incredibly effective in reducing the signs and symptoms of eczema in children under the age of six with moderate to severe cases of the disorder.

It’s the first time it’s a complex biological medicine Like this was tested on this age group.

The medicine in question is dupilumab; In a new study, 162 North American and European children ages 6 months to 6 years with moderate to severe eczema were given dublomab or a placebo over 16 weeks.

More than half of the children who took the drug showed a 75 percent reduction in symptom severity. Itching is greatly reduced, and children can sleep better.

Preschoolers who scratch constantly, get up several times a night with their parents, are irritable and have markedly limited ability to do what other children of their age can do, get so good that they sleep through the night, change their personalities and have a normal life – as it should for infants and children, ” Dermatologist Amy Baller says: from Northwestern University in Illinois.

Dupilumab targets an immune inflammatory pathway important in allergies and is already used to treat eczema in older children and adults, as well as asthma, nasal polyps, and other allergic problems.

So far, it hasn’t been approved as safe or proven to be effective for people under the age of six – roughly 19 percent From this demographic they are believed to have eczema, while 85-90 percent Of those who develop eczema in their lives see the first signs of it before the age of five.

About a third of this age group with eczema suffers from a moderate to severe case of the disorder, accompanied by debilitating itch: these children cannot sleep properly, which leads to all kinds of effects and consequences.

While immunosuppressive medications such as oral steroids are often used for severe cases of eczema, there are concerns about their suitability for young children – in terms of short-term side effects and long-term health complications, According to Baller.

“The group with which we worry most about safety – those under five years old – has not been tested and we have not been able to get it [dupilumab]” Baler says. “The effect for most of these children is significant and at least as good as we’ve seen with the risky immunosuppressive drugs.”

Dupilumab already has a safety profile defined as “excellent”, and no further lab testing is required. It’s now available for babies younger than 6 months old, and a parent or healthcare professional can administer the medication through a monthly dose.

Moreover, researchers believe that it can also have protective effects. Since it takes such an aggressive approach to calming the immune system’s inflammatory response, there’s a good chance that it may also protect against other allergy issues that develop later in life.

Researchers suggest that dupilumab may be useful in dealing with other health problems in younger children – although more studies will be needed to determine how it may be effective.

“The ability to take this drug will greatly improve the quality of life for infants and young children who are severely affected by this disease,” Baler says.

“Atopic dermatitis or eczema is much more than just itchy skin. It’s a devastating disease. The quality of life for severe eczema—not only for children but also for parents—is equivalent to many life-threatening illnesses.”

The research was sponsored by Regeneron Pharmaceuticals and Sanofi, who jointly developed dupilumab, and the study is published in scalpel.